Related Experiment Video
Updated: Aug 9, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
[Fibroblast growth factor (FGF) endocrines and pulmonary fibrogenesis]
M Ghanem1, A Mailleux1, B Crestani2
1Inserm Unité 1152, Université Paris Cité, Paris, France.
Abstract:
As key actors in embryogenesis and organogenesis, fibroblast growth factors (FGFs) can assume a protective or an aggravative role in pulmonary fibrosis pathophysiology. Among the FGFs, endocrine FGFs (FGF19, FGF21 and FGF23), are characterized by low affinity to FGF receptors (FGFRs), enabling them to deploy endocrine activity in several organs. More specifically, their anti-fibrotic role has been reported in liver, kidney or myocardial fibrosis. Endocrine FGFs are of growing interest on account of their potential anti-fibrotic role in pulmonary fibrogenesis, as well. In this review, we aim to summarize current knowledge on the protective effects of endocrine FGFs in pulmonary fibrosis.
Related Concept Videos
Introduction to Fibroblasts
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Fibronectins Connect Cells with ECM
Both proteoglycans and collagen are attached to fibronectin proteins, which, in turn, are attached to integrin proteins. These integrin proteins interact with transmembrane...
TGF - β Signaling Pathway
Regulation of Angiogenesis and Blood Supply
Mitogens and the Cell Cycle

